Famotidine and Antacids for Treatment of Dyspepsia

Launched by STONY BROOK UNIVERSITY · Jan 26, 2024

Keywords

ClinConnect Summary

This clinical trial is studying two treatments for dyspepsia, which is a term for discomfort or pain in the upper stomach, often related to acid reflux. The trial compares intravenous famotidine, a medication that reduces stomach acid, with Maalox or Mylanta, which are over-the-counter antacids you take by mouth. The main goal is to see which treatment can better relieve pain quickly in patients who come to the emergency department with upper abdominal pain. Researchers expect that both treatments will help reduce pain, but they believe that the antacids may work faster.

To participate in this study, you need to be at least 18 years old and have a diagnosis of dyspepsia, with a pain score of 3 or higher when you arrive at the emergency department. However, there are some conditions that would prevent you from joining, such as allergies to the medications, severe kidney issues, being pregnant or nursing, or if you have recently taken certain medications that affect stomach acid. If you join the study, you can expect to receive one of the two treatments and have your pain levels monitored closely. This trial is currently recruiting participants, and it's a great opportunity to help researchers learn more about effective treatments for dyspepsia.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Subject Age ≥ 18 years of age
• • 2. Patient diagnosed with dyspepsia
• • 3. Present at the ED with upper abdominal pain score of at least 3
• Exclusion Criteria:
• • 1. Hypersensitivity to an ingredient in Maalox/ Mylanta or Famotidine
• • 2. Moderate to Severe Renal Insufficiency (precaution)
• • 3. Kidney Failure
• • 4. Pregnant or Nursing
• • 5. Verbal pain score less than 3
• • 6. Inability to tolerate oral medications
• • 7. Bowel Obstruction
• • 8. Proton pump inhibitor within 2 hours of study treatment